Convergence of Targeted Drugs With Genomics-Based Diagnostics to Create New Paradigm for Cancer Treatment
Next-Generation Cancer Diagnostics Market to Grow 22% Annually Through 2025
WELLESLEY, Mass., March 20, 2021 (Newswire.com) - Big Data is our greatest potential weapon in the fight against cancer. Despite countless advancements, cancer remains the second-leading cause of death worldwide, and the burden on patients, families and society is profound.
Advanced diagnostics for cancer represent a major market opportunity for life sciences companies, according to the BCC Research report, Next-Generation Cancer Diagnostics: Technologies and Global Markets.
Three pressing needs in cancer diagnostics loom large: The first is earlier stage identification, identifying cancer before it has spread to other parts of the body. The second is a more accurate classification of suspicious lesions or nodules. Thirdly, we need cancer diagnostics that guide therapy decisions.
Report Highlights
- The global market for next-generation cancer diagnostics is expected to grow from $6.2 billion in 2020 to $16.7 billion by 2025 with a compound annual growth rate (CAGR) of 21.9%.
- Next-generation breast cancer diagnostics is expected to grow from $1.6 billion in 2020 to $3.1 billion by 2025 with a CAGR of 13.9%.
- Analysis of key market players: Abbott Laboratories, Thermo Fisher Scientific and Danaher Corp.
Explore the full report here: https://www.bccresearch.com/market-research/biotechnology/next-generation-cancer-diagnostics-technologies-report.html.
About BCC Research
BCC Research publishes market research reports that provide organizations with intelligence to drive smart business decisions. By partnering with industry experts worldwide, BCC Research provides unbiased measurements and assessments of global markets covering current and emerging industrial and technology sectors. For more information about BCC Research, visit bccresearch.com.
Source: BCC Research
